Top

Published in:

Open Access 01-12-2021 | Acute Respiratory Distress-Syndrome | Review

Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps

Authors: Daniele De Luca, Paola Cogo, Martin C. Kneyber, Paolo Biban, Malcolm Grace Semple, Jesus Perez-Gil, Giorgio Conti, Pierre Tissieres, Peter C. Rimensberger

Published in: Critical Care | Issue 1/2021

Abstract

Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have different age-specific characteristics and definitions. Trials on surfactant for ARDS in children and neonates have been performed well before the PARDS and NARDS definitions and yielded conflicting results. This is mainly due to heterogeneity in study design reflecting historic lack of pathobiology knowledge. We reviewed the available clinical and preclinical data to create an expert consensus aiming to inform future research steps and advance the knowledge in this area. Eight trials investigated the use of surfactant for ARDS in children and ten in neonates, respectively. There were improvements in oxygenation (7/8 trials in children, 7/10 in neonates) and mortality (3/8 trials in children, 1/10 in neonates) improved. Trials were heterogeneous for patients’ characteristics, surfactant type and administration strategy. Key pathobiological concepts were missed in study design. Consensus with strong agreement was reached on four statements:

There are sufficient preclinical and clinical data to support targeted research on surfactant therapies for PARDS and NARDS. Studies should be performed according to the currently available definitions and considering recent pathobiology knowledge.

PARDS and NARDS should be considered as syndromes and should be pre-clinically studied according to key characteristics, such as direct or indirect (primary or secondary) nature, clinical severity, infectious or non-infectious origin or patients’ age.

Explanatory should be preferred over pragmatic design for future trials on PARDS and NARDS.

Different clinical outcomes need to be chosen for PARDS and NARDS, according to the trial phase and design, trigger type, severity class and/or surfactant treatment policy.

We advocate for further well-designed preclinical and clinical studies to investigate the use of surfactant for PARDS and NARDS following these principles.

Available only for authorised users

De Luca D, van Kaam AH, Tingay DG, Courtney SE, Danhaive O, Carnielli VP, et al. The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity. Lancet Respir Med. 2017;5:657–66.PubMedCrossRef

Khemani RG, Smith LS, Zimmerman JJ, Erickson S. Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology. Pediatr Crit Care Med. 2015;16:S23-40.PubMedCrossRef

De Luca D. Personalising care of acute respiratory distress syndrome according to patients’ age. Lancet Respir Med. 2019;7:100–1.PubMedCrossRef

Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. 2014;306:L709–25.PubMedPubMedCentralCrossRef

Millar FR, Summers C, Griffiths MJ, Toshner MR, Proudfoot AG. The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. Thorax. 2016;71:462–73.PubMedCrossRef

Raghavendran K, Willson D, Notter RH. Surfactant therapy for acute lung injury and acute respiratory distress syndrome. Crit Care Clin. 2011;27:525–59.PubMedPubMedCentralCrossRef

De Luca D, Piastra M, Chidini G, Tissieres P, Calderini E, et al. On behalf of Respiratory Section of the European Society for Pediatric Neonatal Intensive Care (ESPNIC). The use of the Berlin definition for acute respiratory distress syndrome during infancy and early childhood: multicenter evaluation and expert consensus. Intensive Care Med. 2013;39:2083–91.

Khemani RG. Khemani RG, Smith L, Lopez-Fernandez YM, Kwok J, Morzov R, Klein MJ, et al. Pediatric Acute Respiratory Distress syndrome Incidence and Epidemiology (PARDIE) Investigators; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study. Lancet Respir Med. 2019;7:115–128. Erratum in: Lancet Respir Med. 2018 Nov 13: Erratum in: Lancet Respir Med. 2019;7:e12.

Kneyber MCJ, Zhang H, Slutsky AS. Ventilator-induced lung injury: similarity and differences between children and adults. Am J Respir Crit Care Med. 2014;190:258–65.PubMed

10.

Günther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res. 2001;2:353–64.PubMedPubMedCentralCrossRef

11.

De Luca D, Lopez-Rodriguez E, Minucci A, Vendittelli F, Gentile L, Stival E, et al. Clinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants. Crit Care. 2013;17:R163.PubMedPubMedCentralCrossRef

12.

Touqui L, Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Mol Med Today. 1999;5:244–9.PubMedCrossRef

13.

Cogo PE, Toffolo GM, Ori C, Vianello A, Chierici M, Gucciardi A, et al. Surfactant disaturated-phosphatidylcholine kinetics in acute respiratory distress syndrome by stable isotopes and a two-compartment model. Respir Res. 2007;8:13.PubMedPubMedCentralCrossRef

14.

Calfee CS, Janz DR, Bernard GR, May AK, Kangelaris KN, Matthay MA, et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest. 2015;147:1539–48.PubMedCrossRef

15.

Moussa MD, Santonocito C, Fagnoul D, Donadello K, Pradier O, Gaussem P, et al. Evaluation of endothelial damage in sepsis-related ARDS using circulating endothelial cells. Intensive Care Med. 2015;41:231–8.PubMedCrossRef

16.

Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611–20.PubMedPubMedCentralCrossRef

17.

Yehya N, Keim G, Thomas NJ. Subtypes of pediatric acute respiratory distress syndrome have different predictors of mortality. Intensive Care Med. 2018;44:1230–9.PubMedPubMedCentralCrossRef

18.

Santhakumaran S, Gordon A, Prevost AT, O’Kane C, McAuley DF, Shankar-Hari M. Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. Crit Care. 2019;23:156.PubMedPubMedCentralCrossRef

19.

Shankar-Hari M, Rubenfeld GD. Population enrichment for critical care trials: phenotypes and differential outcomes. Curr Opin Crit Care. 2019;25:489–97.PubMedCrossRef

20.

Tamburro RF, Kneyber MCJ. Pulmonary specific ancillary treatment for pediatric acute respiratory distress syndrome: proceedings from the pediatric acute lung injury consensus conference. Pediatr Crit Care Med. 2015;16:S61-72.PubMedCrossRef

21.

Kneyber MCJ, de Luca D, Calderini E, Jarreau P-H, Javouhey E, et al. on behalf of the section Respiratory Failure of the European Society for Paediatric and Neonatal Intensive Care. Recommendations for mechanical ventilation of critically ill children from the Paediatric Mechanical Ventilation Consensus Conference (PEMVECC). Intensive Care Med. 2017;43:1764–80.

22.

Ardell S, Pfister RH, Soll R. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2015;(5):CD000144.

23.

Echaide M, Autilio C, Arroyo R, Perez-Gil J. Restoring pulmonary surfactant membranes and films at the respiratory surface. Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1725–1739.

24.

Quaker Foundations of Leadership. A comparison of Quaker-based consensus and Robert’s rules of order. Richmond (VI) USA: Earlham College; 1999.

25.

Thomas NJ, Spear D, Wasserman E, Pon S, Markovitz B, Singh AR, et al. CALIPSO: a randomized controlled trial of calfactant for acute lung injury in pediatric stem cell and oncology patients. Biol Blood Marrow Transplant. 2018;24:2479–86.PubMedCrossRef

26.

Tridente A, De Martino L, De Luca D. Porcine vs bovine surfactant therapy for preterm neonates with RDS: systematic review with biological plausibility and pragmatic meta-analysis of respiratory outcomes. Respir Res. 2019;20(1):28.PubMedPubMedCentralCrossRef

27.

Willson DF, Zaritsky A, Bauman LA, Dockery K, James RL, Conrad D, et al. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med. 1999;27:188–95.PubMedCrossRef

28.

Möller JC, Schaible T, Roll C, Schiffmann J-H, Bindl L, Schrod L, et al. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Intensive Care Med. 2003;29:437–46.PubMedPubMedCentralCrossRef

29.

Yapıcıoğlu H, Yıldızdaş D, Bayram İ, Sertdemir Y, Yılmaz HL. The use of surfactant in children with acute respiratory distress syndrome: efficacy in terms of oxygenation, ventilation and mortality. Pulm Pharm Ther. 2003;16:327–33.CrossRef

30.

Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005;293:470–6.PubMedCrossRef

31.

Thomas NJ, Guardia CG, Moya FR, Cheifetz IM, Markovitz B, Cruces P, et al. A pilot, randomized, controlled clinical trial of lucinactant, a peptide-containing synthetic surfactant, in infants with acute hypoxemic respiratory failure. Pediatr Crit Care Med. 2012;13:646–53.PubMedCrossRef

32.

Willson DF, Thomas NJ, Tamburro R, Truemper E, Truwit J, Conaway M, et al. Pediatric calfactant in acute respiratory distress syndrome trial. Pediatr Crit Care Med. 2013;14:657–65.PubMedCrossRef

33.

Rodríguez-Moya VS, Gallo-Borrero CM, Santos-Áreas D, Prince-Martínez IA, Díaz-Casañas E, López-Herce CJ. Exogenous surfactant and alveolar recruitment in the treatment of the acute respiratory distress syndrome: Treatment of the ARDS. Clin Resp J. 2017;11:1032–9.CrossRef

34.

Lotze A, Knight GR, Martin GR, Bulas DI, Hull WM, O’Donnell RM, et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr. 1993;122:261–8.PubMedCrossRef

35.

Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics. 1996;97:48–52.PubMed

36.

Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr. 1998;132:40–7.

37.

Chinese Collaborative Study Group for Neonatal Respiratory Diseases. Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr. 2005;94:896–902.

38.

Chang M, Lu H-Y, Xiang H, Lan H-P. Clinical effects of different ways of mechanical ventilation combined with pulmonary surfactant in treatment of acute lung injury/acute respiratory distress syndrome in neonates: a comparative analysis. Chin J Contemp Pediatr. 2016;18:1069–74.

39.

Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, et al. A multicenter, randomized, controlled trial comparing surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics. 2002;109:1081–7.PubMedCrossRef

40.

Gadzinowski J, Kowalska K, Vidyasagar D. Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO. J Perinatol. 2008;28:S56-66.PubMedCrossRef

41.

Dargaville PA, Copnell B, Mills JF, Haron I, Lee JKF, Tingay DG, et al. Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome. J Pediatr. 2011;158:383–9.PubMedCrossRef

42.

Bandiya P, Nangia S, Saili A. Surfactant lung lavage vs. standard care in the treatment of meconium aspiration syndrome: a randomized trial. J Trop Pediatr. 2019;65:114–21.

43.

Rong Z, Mo L, Pan R, Zhu X, Cheng H, Li M, et al. Bovine surfactant in the treatment of pneumonia-induced–neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: a multicentre, randomized, assessor-blinded, placebo-controlled trial. Eur J Pediatr. 2020 Oct 21:1–9. doi: https://doi.org/10.1007/s00431-020-03821-2. Epub ahead of print.

44.

Tamburro RF, Thomas NJ, Pon S, Jacobs BR, DiCarlo JV, Markovitz BP, et al. Post hoc analysis of calfactant use in immunocompromised children with acute lung injury: Impact and feasibility of further clinical trials. Pediatr Crit Care Med. 2008;9:459–64.PubMedCrossRef

45.

ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33.

46.

De Luca D, Shankar-Aguilera S, Autilio C, Raschetti R, Vedovelli L, Fitting C, et al. Surfactant-secreted phospholipase A 2 interplay and respiratory outcome in preterm neonates. Am J Physiol Lung Cell Mol Physiol. 2020;319:L95-104.PubMedCrossRef

47.

Autilio C, Echaide M, Shankar-Aguilera S, Bragado R, Amidani D, Salomone F, et al. Surfactant injury in the early phase of severe meconium aspiration syndrome. Am J Respir Cell Mol Biol. 2020;63:327–37.PubMedCrossRef

48.

Spengler D, Rintz N, Krause MF. An Unsettled Promise: The Newborn Piglet Model of Neonatal Acute Respiratory Distress Syndrome (NARDS). Physiologic Data and Systematic Review. Front Physiol. 2019;10:1345.

49.

Ballard-Croft C, Wang D, Sumpter LR, Zhou X, Zwischenberger JB. Large-animal models of acute respiratory distress syndrome. Ann Thorac Surg. 2012;93:1331–9.PubMedCrossRef

50.

Yehya N. Lessons learned in acute respiratory distress syndrome from the animal laboratory. Ann Transl Med. 2019;7:503–503.PubMedPubMedCentralCrossRef

51.

Elsayed YN, Hinton M, Graham R, Dakshinamurti S. Lung ultrasound predicts histological lung injury in a neonatal model of acute respiratory distress syndrome. Pediatr Pulmonol. 2020;55:2913–23.PubMedCrossRef

52.

Randolph AG. Management of acute lung injury and acute respiratory distress syndrome in children. Crit Care Med. 2009;37:2448–54.PubMedCrossRef

53.

Bindl L, Buderus S, Dahlem P, Demirakca S, Goldner M, Huth R, et al. Gender-based differences in children with sepsis and ARDS: The ESPNIC ARDS Database Group. Intensive Care Med. 2003;29:1770–3.PubMedCrossRef

54.

Luo L, Shaver CM, Zhao Z, Koyama T, Calfee CS, Bastarache JA, et al. Clinical predictors of hospital mortality differ between direct and indirect ARDS. Chest. 2017;151:755–63.PubMedCrossRef

55.

Wong JJ-M, Phan HP, Phumeetham S, Ong JSM, Chor YK, Qian S, et al. Risk stratification in pediatric acute respiratory distress syndrome: a multicenter observational study. Crit Care Med. 2017;45:1820–8.

56.

Grotberg JB, Filoche M, Willson DF, Raghavendran K, Notter RH. Did reduced alveolar delivery of surfactant contribute to negative results in adults with acute respiratory distress syndrome? Am J Resp Crit Care Med. 2017;195:538–40.PubMedCrossRefPubMedCentral

57.

Sinha P, Calfee CS. Phenotypes in acute respiratory distress syndrome: moving towards precision medicine. Curr Opin Crit Care. 2019;25:12–20.PubMedPubMedCentralCrossRef

58.

De Luca D, Harrison DA, Peters MJ. ‘Lumping or splitting’ in paediatric acute respiratory distress syndrome (PARDS). Intensive Care Med. 2018;44:1548–50.PubMedCrossRef

59.

Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464–75.PubMedCrossRef

60.

The bronchiolitis endotracheal surfactant study (BESS) [Internet]. Available from: http://www.isrctn.com/ISRCTN11746266. Accessed on January 22, 2021

61.

Taut FJH, Rippin G, Schenk P, Findlay G, Wurst W, Häfner D, et al. A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy. Chest. 2008;134:724–32.PubMedCrossRef

62.

De Luca D, Piastra M, Tosi F, Pulitano S, Mancino A, Genovese O, et al. Pharmacological therapies for pediatric and neonatal ALI/ARDS: an evidence-based review. Curr Drug Targets. 2012;13:906–16.PubMedCrossRef

63.

De Luca D, Vázquez-Sánchez S, Minucci A, Echaide M, Piastra M, Conti G, et al. Effect of whole body hypothermia on inflammation and surfactant function in asphyxiated neonates. Eur Resp J. 2014;44:1708–10.CrossRef

64.

Ravasio A, Cruz A, Pérez-Gil J, Haller T. High-throughput evaluation of pulmonary surfactant adsorption and surface film formation. J Lipid Res. 2008;49:2479–88.PubMedCrossRef

65.

Autilio C, Echaide M, Benachi A, Marfaing-Koka A, Capoluongo ED, Pérez-Gil J, et al. A noninvasive surfactant adsorption test predicting the need for surfactant therapy in preterm infants treated with continuous positive airway pressure. J Pediatr. 2017;182:66–73.PubMedCrossRef

66.

Dahmer MK, Flori H, Sapru A, Kohne J, Weeks HM, Curley MAQ, et al. Surfactant Protein D is associated with severe pediatric ARDS, prolonged ventilation, and death in children with acute respiratory failure. Chest. 2020;158:1027–35.PubMedCrossRefPubMedCentral

67.

Ward SL, Dahmer MK, Weeks HM, Sapru A, Quasney MW, Curley MAQ, et al. Association of patient weight status with plasma surfactant protein D, a biomarker of alveolar epithelial injury, in children with acute respiratory failure. Pediatr Pulmonol. 2020;55:2730–6.PubMedCrossRefPubMedCentral

68.

De Luca D, Autilio C, Pezza L, Shankar-Aguilera S, Tingay D, Carnielli V. Personalised medicine for the management of RDS in preterm neonates. Neonatology. 2021 in press;

69.

Germain N, Aballéa S, Toumi M. Measuring health-related quality of life in young children: how far have we come? J Mark Access Health Policy. 2019;22:7:1618661. Erratum in: J Mark Access Health Policy. 2019;7:1626572.

70.

Weed DL, Hursting SD. Biologic plausibility in causal inference: current method and practice. Am J Epidemiol. 1998;147:415–25.PubMedCrossRef

71.

Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015;12:14.PubMedPubMedCentralCrossRef

72.

Contentin L, Ehrmann S, Giraudeau B. Heterogeneity in the definition of mechanical ventilation duration and ventilator-free days. Am J Resp Crit Care Med. 2014;189:998–1002.PubMedCrossRef

73.

Enhörning G, Robertson B. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics. 1972;50:58–66.PubMed

74.

Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980;1:55–9.PubMedCrossRef

75.

Newth CJ, Stretton M, Deakers TW, Hammer J. Assessment of pulmonary function in the early phase of ARDS in pediatric patients. Pediatr Pulmonol. 1997;23:169–75.PubMedCrossRef

76.

Wirbelauer J, Speer CP. The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome. J Perinatol. 2009;29(Suppl 2):S18-22.PubMedCrossRef

77.

Faix RG, Viscardi RM, DiPietro MA, Nicks JJ. Adult respiratory distress syndrome in full-term newborns. Pediatrics. 1989;83:971–6.PubMed

78.

Ashbaugh DG, Boyd Bigelow D, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;290:319–23.CrossRef

79.

Lachmann B. Animal models and clinical pilot studies of surfactant replacement in adult respiratory distress syndrome. Eur Respir J Suppl. 1989;3:98s–103s.PubMed

80.

Marraro G. Use of surfactant in respiratory diseases in neonates and infants. Cah Anesthesiol. 1994;42:159–66 [article in French].

81.

Kitsiouli E, Nakos G, Lekka ME. Phospholipase A2 subclasses in acute respiratory distress syndrome. Biochim Biophys Acta. 2009;1792(10):941–53.PubMedCrossRef

82.

Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, et al. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest. 1998;102:1152–60.PubMedPubMedCentralCrossRef

83.

Berger A, Havet N, Vial D, Arbibe L, Dumarey C, Watson ML, et al. Dioleylphosphatidylglycerol inhibits the expression of type II phospholipase A2 in macrophages. Am J Respir Crit Care Med. 1999;159:613–8.PubMedCrossRef

84.

Pilon AL. Rationale for the development of recombinant Human CC10 as a therapeutic for inflammatory and fibrotic disease. Ann N Y Acad Sci. 2000;923:280–99.PubMedCrossRef

85.

Kishore U, Bernal AL, Kamran MF, Saxena S, Singh M, Sarma PU, et al. Surfactant proteins SP-A and SP-D in human health and disease. Arch Immunol Ther Exp (Warsz). 2005;53:399–417.

86.

von Bismarck P, Klemm K, García Wistädt C-F, Winoto-Morbach S, Schütze S, Krause MF. Selective NF-κB inhibition, but not dexamethasone, decreases acute lung injury in a newborn piglet airway inflammation model. Pulm Pharm Ther. 2009;22:297–304.CrossRef

87.

Preuß S, Scheiermann J, Stadelmann S, Omam FD, Winoto-Morbach S, Lex D, et al. 18:1/18:1-Dioleoyl-phosphatidylglycerol prevents alveolar epithelial apoptosis and profibrotic stimulus in a neonatal piglet model of acute respiratory distress syndrome. Pulm Pharm Ther. 2014;28:25–34.CrossRef

88.

De Luca D, Minucci A, Trias J, Tripodi D, Conti G, Zuppi C, et al. Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury. J Clin Pharmacol. 2012;52:729–37.PubMedCrossRef

89.

De Luca D, Minucci A, Piastra M, Cogo PE, Vendittelli F, Marzano L, et al. Ex vivo effect of varespladib on secretory phospholipase A2 Alveolar activity in infants with ARDS. PLoS ONE. 2012;7:e47066.PubMedPubMedCentralCrossRef

90.

Deliloglu B, Tuzun F, Cengiz MM, Ozkan H, Duman N. Endotracheal surfactant combined with budesonide for neonatal ARDS. Front Pediatr. 2020;8:210.PubMedPubMedCentralCrossRef

91.

Triggiani M, Granata F, Petraroli A, Loffredo S, Frattini A, Staiano RI, et al. Inhibition of secretory phospholipase A2-induced cytokine production in human lung macrophages by budesonide. Int Arch Allergy Immunol. 2009;150:144–55.PubMedCrossRef

92.

Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and meta-analysis. Pediatr Pulmonol. 2017;52:968–75.PubMedCrossRef

93.

Foligno S, De Luca D. Porcine versus bovine surfactant therapy for RDS in preterm neonates: pragmatic meta-analysis and review of physiopathological plausibility of the effects on extra-pulmonary outcomes. Respir Res. 2020;21(1):8.PubMedPubMedCentralCrossRef

94.

Cogo PE, Facco M, Simonato M, Verlato G, Rondina C, Baritussio A, et al. Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome. Pediatrics. 2009;124:e950–7.PubMedCrossRef

95.

Cogo PE, Facco M, Simonato M, De Luca D, De Terlizi F, Rizzotti U, et al. Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome. Intensive Care Med. 2011;37:510–7.PubMedCrossRef

96.

Sun Y, Wang Y-Q, Yang R, Zhu J-J, Le Y-Y, Zhong J-G, et al. Exogenous porcine surfactants increase the infiltration of leukocytes in the lung of rats. Pulm Pharm Ther. 2009;22:253–9.CrossRef

97.

Schrod L, Hornemann F, von Stockhausen HB. Chemiluminescence activity of phagocytes from tracheal aspirates of premature infants after surfactant therapy. Acta Paediatr. 1996;85:719–23.PubMedCrossRef

98.

Wolfler A, Piastra M, Amigoni A, Santuz P, Gitto E, Rossetti E, et al. A shared protocol for porcine surfactant use in pediatric acute respiratory distress syndrome: a feasibility study. BMC Pediatr. 2019;19:203.PubMedPubMedCentralCrossRef

99.

Biban P, Conti G, Wolfler AM, Carlassara S, Gitto E, Rulli I, et al. Efficacy and safety of exogenous surfactant therapy in patients under 12 months of age invasively ventilated for severe bronchiolitis (SURFABRON): protocol for a multicentre, randomised, double-blind, controlled, non-profit trial. BMJ Open. 2020;10:e038780.PubMedPubMedCentralCrossRef

100.

Choi HJ, Hahn S, Lee J, Park B-J, Lee SM, Kim H-S, et al. Surfactant LAVAGE THERAPY FOR MECONIUM ASPIRATION SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS. Neonatology. 2012;101:183–91.PubMedCrossRef

101.

Henn R, Fiori RM, Fiori HH, Pereira MR, Colvero MO, Ramos Garcia PC, et al. Surfactant with and without bronchoalveolar lavage in an experimental model of meconium aspiration syndrome. J Perinat Med. 2016;44:685–9.PubMedCrossRef

Title: Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps
Authors: Daniele De Luca
Paola Cogo
Martin C. Kneyber
Paolo Biban
Malcolm Grace Semple
Jesus Perez-Gil
Giorgio Conti
Pierre Tissieres
Peter C. Rimensberger
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Acute Respiratory Distress-Syndrome
Published in: Critical Care / Issue 1/2021
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-021-03489-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Impact of withholding early parenteral nutrition in adult critically ill patients on ketogenesis in relation to outcome

Slicing and dicing ARDS: we almost forgot the lungs

Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients

Evaluation of right ventricular function and driving pressure with blood gas analysis could better select patients eligible for VV ECMO in severe ARDS

Electrical impedance tomography captures heterogeneous lung ventilation that may be associated with ineffective inspiratory efforts

Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm